Gradient Investments’s Actinium Pharmaceuticals ATNM Stock Holding History

Gradient Investments’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-66	Closed	-$335	–	1279
2023 Q4	$335	Hold	66	–	–	﹤0.01%	1653
2023 Q3	$391	Hold	66	–	–	﹤0.01%	1597
2023 Q2	$490	Hold	66	–	–	﹤0.01%	1540
2023 Q1	$624	Hold	66	–	–	﹤0.01%	1256
2022 Q4	$703	Hold	66	–	–	﹤0.01%	1256
2022 Q3	$0	Hold	66	–	–	﹤0.01%	1342
2022 Q2	$0	Hold	66	–	–	﹤0.01%	1214
2022 Q1	$0	Hold	66	–	–	﹤0.01%	1176
2021 Q4	$0	Hold	66	–	–	﹤0.01%	1225
2021 Q3	$1K	Hold	66	–	–	﹤0.01%	1049
2021 Q2	$1K	Hold	66	–	–	﹤0.01%	1041
2021 Q1	$1K	Hold	66	–	–	﹤0.01%	1053
2020 Q4	$1K	Hold	66	–	–	﹤0.01%	1013
2020 Q3	$1K	Buy	+66	New	+$728	﹤0.01%	1018

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Gradient Investments's ATNM Position: Q1 2024 in Review

Gradient Investments sold out of Actinium Pharmaceuticals (ATNM) in Q1 2024, closing a stake of 66 shares — an estimated $335 sold.

Gradient Investments first reported a position in ATNM in Q3 2020 and held it in 14 quarters. The position peaked at $1K in Q3 2021. 67 funds tracked by Wall St. Rank hold ATNM as of Q1 2024.

Gradient Investments reported no remaining Actinium Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Gradient Investments sold 66 Actinium Pharmaceuticals shares in Q1 2024, an estimated $335.
Gradient Investments first reported a position in Actinium Pharmaceuticals in Q3 2020 and held it in 14 quarters.
Gradient Investments's Actinium Pharmaceuticals position peaked at $1K in Q3 2021.
67 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2024.

Based on Gradient Investments's 13F filing for Q1 2024, filed 23 Apr 2024.